Matherly Larry H, Goldman David I
Experimental and Clinical Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Department of Pharmacology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.
Vitam Horm. 2003;66:403-56. doi: 10.1016/s0083-6729(03)01012-4.
The chapter reviews the current understanding of the transport mechanisms for folates in mammalian cells--their molecular identities and organization, tissue expression, regulation, structures, and their kinetic and thermodynamic properties. This encompasses a variety of diverse processes. Best characterized is the reduced folate carrier, a member of the SLC19 family of facilitative carriers. But other facilitative organic anion carriers (SLC21), largely expressed in epithelial tissues, transport folates as well. In addition to these bi-directional carrier systems are the membrane-localized folate receptors alpha and beta, that mediate folate uptake unidirectionally into cells via an endocytotic process. There are also several transporters, typified by the family of multidrug resistance-associated proteins, that unidirectionally export folates from cells. There are transport activities for folates, that function optimally at low pH, related in part to the reduced folate carrier, with at least one activity that is independent of this carrier. The reduced folate carrier-associated low-pH route mediates intestinal folate transport. This review considers how these different transport processes contribute to the generation of transmembrane folate gradients and to vectorial flows of folates across epithelia. The role of folate transporters in mouse development, as assessed by homologous deletion of folate receptors and the reduced folate carrier, is described. Much of the focus is on antifolate cancer chemotherapeutic agents that are often model surrogates for natural folates in transport studies. In particular, antifolate transport mediated by the reduced folate carrier is a major determinant of the activity of, and resistance to, these agents. Finally, many of the key in vitro findings on the properties of antifolate transporters are now beginning to be extended to patient specimens, thus setting the stage for understanding response to these drugs in the clinical setting at the molecular level.
本章回顾了目前对哺乳动物细胞中叶酸转运机制的理解——它们的分子特性与结构、组织表达、调控、结构以及动力学和热力学性质。这涵盖了多种不同的过程。研究最为透彻的是还原型叶酸载体,它是易化载体SLC19家族的一员。但其他主要在上皮组织中表达的易化有机阴离子载体(SLC21)也能转运叶酸。除了这些双向载体系统外,还有膜定位的叶酸受体α和β,它们通过内吞过程介导叶酸单向摄取进入细胞。也有几种转运蛋白,以多药耐药相关蛋白家族为代表,它们将叶酸从细胞中单向输出。存在一些在低pH下发挥最佳功能的叶酸转运活性,部分与还原型叶酸载体相关,且至少有一种活性与该载体无关。与还原型叶酸载体相关的低pH途径介导肠道叶酸转运。本综述探讨了这些不同的转运过程如何促成跨膜叶酸梯度的产生以及叶酸跨上皮细胞的向量流动。还描述了通过叶酸受体和还原型叶酸载体的同源缺失评估的叶酸转运蛋白在小鼠发育中的作用。重点大多放在抗叶酸癌症化疗药物上,它们在转运研究中常作为天然叶酸的模型替代物。特别是,由还原型叶酸载体介导的抗叶酸转运是这些药物活性和耐药性的主要决定因素。最后,许多关于抗叶酸转运蛋白特性的关键体外研究结果现在正开始扩展到患者样本,从而为在分子水平上理解临床环境中对这些药物的反应奠定了基础。